Approximately two thirds of cases of hepatic flow obstruction are due to myeloproliferative disorders. Restoration of hepatic blood flow is the essential goal of treatment. Thrombolytic therapy seems to achieve good results at least in selected cases. A 32year-old woman is presented, with an intermittent increase in platelet count (526-725 x 109/L), two previous spontaneous abortions and acute symptomatic occlusion of hepatic veins, and in whom a diagnosis of essential thrombocythemia was initially carried out in agreement with the polycythemia vera study group criteria. She received recombinant tissue plasminogen activator followed by heparin with restoration of normal hepatic outflow. Asymptomatic re-occlusion of
the hepatic veins was observed 1 year later, despite adequate continuous warfarin treatment. Angiography showed marked narrowing of the intrahepatic cava vein due to extrinsic compression by an enlarged liver, not due to a new thrombosis so that no specific intervention could be performed. In the presence of a clearly documented hepatic vein thrombosis, thrombolytic therapy should be considered. The patient was given low-molecular-weight heparin with a dramatic reduction in previously elevated fibrinogen level and a good control of the hepatic function. Key Words: Essential thrombocythemia-Budd-Chiari syndrome-Thrombolytic therapy. and preventing gastrointestinal bleeding. Thrombolytic therapy, associated or not associated with angioplasty, seems to achieve good results at least in selected cases of HVO (Table 1) .
We report a case of Budd-Chiari syndrome with intermittently elevated platelet count, successfully treated with systemic recombinant tissue plasminogen activator (r-tPA), but recurring despite subsequent adequate warfarin treatment.
CASE REPORT
A 32-year-old female was admitted to our hospital in March 1999 because of cardio-circulatory distress with severe hypotension (60/40 mm Hg), neurologic deterioration, and acute liver and renal failure. Her history was remarkable for a spontaneous abortion at the age of 26 and a nonviable delivery at age 30. Histologic evaluation showed multiple placental infarctions in both instances. The patient had received oral Angiography of the cava vein showed a floating thrombus involving the intrahepatic veins and the inferior cava vein up to the right atrium. The retrohepatic cava vein was narrowed because of hepatic hypertrophy. The patient was given systemic thrombolytic therapy with r-tPA (Actylise, Boeringher Ingelheim; intravenous bolus of 10 mg followed by 90 mg infused over 2 hours) 3 days after the onset of clinical symptoms; she was then put on heparin over 19 days (activated partial thromboplastin time around 60 seconds) and eventually on warfarin (International Normalized Ratio [INR], 2-3). Thrombolysis induced a rapid dissolution of the thrombus in both intrahepatic and inferior cava veins, with normalization of hepatic and renal function. Daily color Doppler studies showed persistence of normal hepatic outflow.
At thrombosis, the platelet count was within reference limits; however, retrospective analysis of hematologic tests showed that between 1990 and 1997 the patient had a mild increase in platelet count (526-725 x 109/L) with no other alteration of complete blood cell count on several occasions. The hypothesis of an underlying myeloproliferative disorder was challenged: although bone marrow megakaryocytes were large, dysplastic, and increased in number, no alteration was observed at cytometric analysis nor on peripheral blood smear; blood erythrocyte volume, platelet serotonin content (3 A,M! 109/platelets), serum erythropoietin (31 ng/mL), and thrombopoietin (34.3 pg/mL) levels were all within normal limits; platelet function, as studied by aggregation induced by adrenaline 10 AtM (71%), adenosine diphosphate 2,M (58%), and collagen 2 ,ug (28.6) , was normal and no irondeficiency anemia, nor alteration of iron stores in the bone marrow were documented. Spontaneous erythroid colony growth was not demonstrated. No increase in bone marrow reticuline was observed at trephine bone biopsy. Karyotype, evaluated by classical cytogenetic analysis on bone marrow samples, by polymerase chain reaction for the presence of bcr/abl fusion transcript and by fluorescence in situ hybridization, did not show any alteration. No clinical data suggestive of paroxymal nocturnal hemoglobinuria were recorded. Inherited and autoimmune thrombophilic states were also excluded.
Plasma levels of antithrombin activity, fibrinogen, protein C and S activity and antigen, plasminogen activity, plasminogen activator inhibitor activity, activated protein C resistance sensitivity ratio, euglobulin lysis time, homocysteine, anti-phospholipid autoantibodies, and hemoglobin electrophoresis results were normal. No positive molecular test result for the A2021OG variant of prothrombin was documented. No sign of reactive thrombocytosis nor of congenital metabolic or viral hepatic dysfunction was observed. In particular, inflammatory indexes (erythrocytes sedimentation rate, C-reactive protein, fibrinogen, xc2-globulin), plasma iron, transferrin, ferritin, ceruloplasmin, serum copper, oca-antitrypsin, anti-hepatits B and C virus antibodies and neoplastic markers were all within reference limits. A diagnosis of essential thrombocythemia was carried out, in agreement with the criteria of the polycythemia vera study group (18) . The patient was discharged and returned to normal life, except she became amenorrheic. In September 1999, she was put on hydroxyurea (HU) because of a progressive increase in platelet count (highest level 568 x 109/L platelets). The control at 9 months showed again normal hepatic and renal function while still on warfarin (INR, 2-3) and HU (500 mg/day). The total blood cell count was normal; platelet count was 243 x 109/L, hematocrit 0.36, hemoglobin 124 g/L, white blood cell count 7.33 x 109/L with normal leukocytes morphology. The patient remained asymptomatic, although persistently amenorrheic, but ultrasound and Doppler examination at 1 year showed re-occlusion of the hepatic veins associated with increased liver volume, particularly involving the left lobe, confirmed with CT. The patient was admitted again and at that time, liver enlargement (4 cm) was present. HU was discontinued because the platelet count was 255 x 109/L and low-molecular-weight heparin (LMWH) was started (enoxaparin 6,000 U subcutaneously, twice daily). Laboratory tests showed adequate anticoagulation (INR, 2.65), HU-related macrocytosis (106 fl), elevation in fibrinogen (9. 3 g/L), serum alkaline phosphatase (381 U./L), gamma-glutamyl transpherase (435 U/L) and amylase (271); the remainder were within reference limits. Luteinizing hormone and follicule-stimulating hormone levels were normal as well and showed adequate response after gonadotropin-releasing hormone challenge. Upper digestive endoscopy showed one distal Fl esophageal varice.
Transjugular cava vein angiography showed marked narrowing of the intra-hepatic tract of such vessel, with irregular profiles due to extrinsic compression (Fig. 1) . Selective catheterization allowed visualization of the right suprahepatic vein only, which had reduced length and caliber, promptly distributing into small serpiginous intraparenchymal branches. It was thus impossible to perform any local treatment, either by stenting or by local thrombolysis. The patient was discharged on LMWH and a progressive decrease in fibrinogen level to 3.4 g/L was observed. At the last control (total follow-up, 45 months) the patient was well, under chronic treatment with LMWH (8,000 UI/day) and no palpable liver or spleen was documented. The total blood cell count was within reference limits (platelet count 381 x 109/L). The gamma-glutamyl transferase (273 U/L) was reduced to approximately about 50% of the initial level. . ,. _ I S 00
DISCUSSION
In western countries most cases of Budd-Chiari syndrome result from thrombosis of the hepatic veins due to myeloproliferative disorders (2-5) rapidly evolving to deterioration (19) . Restoration of hepatic blood outflow is the mainstay of therapy, both to correct sinusoidal and portal venous hypertension and to reduce hepatic ischemia and therefore the severity of liver failure (1) . After the initial report by Warren and associates (6), a few patients have been treated by thrombolytic therapy, in the presence of clearly documented recent hepatic vein thrombosis, achieving good results in approximately two thirds of cases. However, failure has also been reported. No clear difference in outcome seems to depend on systemic rather than local route of administration, although it has been suggested (13) that direct infusion into the clot through a catheter may yield better results in the superior cava vein syndrome (20) . The choice and dosage of thrombolytic agent, as well as the modalities of subsequent anticoagulation, varied consider- ably so that no gold standard clearly emerged. No particular relationship has been established with the cause of obstruction of hepatic vein outflow. The use of r-tPA, a fibrin-specific thrombolytic agent, in Budd-Chiari syndrome is not widely experienced (14, 15, 17) . We report a case of a young lady with an intermittent elevation in platelet count and two abortions due to placental infarctions and HVO, who benefited by thrombolytic therapy but relapsed despite adequate oral anticoagulant therapy. The dose of r-tPA used by us was higher than that in most other reported cases, but it was in keeping with that used for pulmonary embolism (21) , thus guiding our decision. HU was thus started when the platelet count increased. In fact, recurrent thrombotic complications are common in primary thrombocytosis with previous thrombotic accident (22) and platelet-reductive therapy is indicated to decrease the thrombotic risk (23) . Also a case of HVO in polycythemia vera reported by Cassel (7) was treated with myelosuppressive therapy in association with anticoagulant drugs.
The proposita might be one of the young patients with ET with an anomalous form of the disease, characterized by a mild platelet count increase, high thrombotic risk, and slow disease progression (24, 25) . Non-clonal ET has also been reported in adult patients (26) and we have recently described (27) five pediatric patients in whom we have hypothized, despite the diagnosis of ET strictly according to PVSG criteria, the possibility of an "idiopathic thrombocytosis" without myeloproliferation . It is remarkable that one of the children had a massive thrombosis of the inferior cava vein, leading to Budd-Chiari syndrome.
The lack of a clear image of thrombosis at angiography, which was more consistent with extrinsic vein compression by parenchimal hypertrophy, sways the diagnosis to a primary hepatic etiology. Moreover, despite the initial complete recovery of hepatic outflow and adequate oral anticoagulation, progressive re-obstruction of the hepatic veins developed. Recurrence of thrombosis under warfarin has been long recognized in cancer (28) , but no evidence of malignancy was present in our case. In most reported cases of Budd-Chiari syndrome treated with thrombolytic agents, the follow-up of the patients was very short and no definitive conclusions can be drawn about the final outcome. Only in three cases with PNH (10,14) a follow-up longer than 2 years may suggest a really definitive success of thrombolysis.
In conclusion, in the presence of a clearly documented recent hepatic vein thrombosis, thrombolytic therapy should be considered inferring from validated experience in the treatment of pulmonary embolism with the rationale and guidelines for using r-tPA. Heparin may be more useful than coumarin derivatives.
